Clinical Trial

Cannabinoids for the Reduction of Inflammation and Sickle Cell Related Pain

Study acronym: CRISP
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
A randomized, double blind, study of dronabinol as a palliative agent in the treatment of pain, inflammation, and other complications of sickle cell disease (SCD).
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2022-08-25; most recent amendment 2025-09-29.
Status change: Enrolling by Invitation → Recruiting 2024-07-02
Status change: Recruiting → Enrolling by Invitation 2024-05-10
Status change: Not Yet Recruiting → Recruiting 2022-09-27
Trial Details
NCT Number NCT05519111
Lead Sponsor Icahn School of Medicine at Mount Sinai
Collaborators: National Heart, Lung, and Blood Institute (NHLBI)
Conditions Sickle Cell Disease
Enrollment 60 participants
Start Date 2025-04-03
Primary Completion 2027-04-01 (estimated)
Study Completion 2027-05-01 (estimated)
Updated on ClinicalTrials.gov 2025-10-02